Figure 4.

Anti-CD137 mAb treatment protects mice from developing proteinuria. Urine was collected from mice in each of the three groups enrolled in the serum anti-dsDNA autoantibody studies described in Figure 1 and tested for protein content by the Albustix method as described in Methods. (a–c) Ovals represent untreated mice and squares represent mice treated with anti-CD137 mAb’s. (a) One injection of anti-CD137 mAb was given at 8 weeks of age. (b) Mice received seven injections of anti-CD137 mAb’s beginning at 8 weeks of age and continuing once every third week. (c) Mice received their first of three anti-CD137 mAb injections at 25 weeks of age and one thereafter every third week for a total of three injections. All injections were administered intraperitoneally at a dose of 200 μg.